Anzeige
Mehr »
Freitag, 10.04.2026 - Börsentäglich über 12.000 News
Research Capital bestätigt $3,00 Kursziel - FUTR zündet die nächste Stufe: Vom Fintech zur globalen Finanzplattform
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
02.04.BioNTech telegraphs closure of Singapore vaccine facility amid efforts to 'align capacity'
02.04.Rising Stars: The Trade Desk's Elizabeth Keenan finds the rhythm in music and media
02.04.Trump eyes 100% tariff rate for companies that have not struck MFN deals: Bloomberg
02.04.Poland, Romania must pay Pfizer $2.2B in fight over contested COVID vaccine doses: Belgian court
02.04.Lilly's obesity pill Foundayo gains early blockbuster forecast as analysts float 5M+ prescriptions in 2026
02.04.Another AstraZeneca Emerald glimmers as Imfinzi, Imjudo delay liver cancer progression
02.04.Glenmark goes direct with new US Ryaltris marketing plan as it drops partner model
02.04.German CDMO Adragos buys French sterile injectables plant from Sanofi
02.04.Bayer rejigs marketing claims after recommendation from US advertising body
02.04.Regulatory tracker: Vertex secures broader FDA labels for cystic fibrosis meds Alyftrek, Trikafta
01.04.Lilly answers Novo's GLP-1 pill with highly anticipated FDA nod for Foundayo
01.04.Novo's Wegovy nets cardio nod from UK cost gatekeeper, adding 1M+ eligible patients
01.04.Evotec hires exec with AI experience to lead rebooted commercial team
31.03.FDA flags serious liver injury cases, 8 deaths with 'reasonable' link to Amgen's Tavneos
31.03.Novo Nordisk cuts 400 roles at troubled Bloomington site
31.03.Iterum initiates wind-down after failure to offload antibiotic with sluggish sales
31.03.API supplier BASF raises prices up to 20% in response to rising energy, raw material costs
31.03.Biogen, eyeing swift commercial tailwind, ponies up $5.6B for Apellis and its 2 approved meds
31.03.Insulet hires Stryker vet, reinstating commercial chief role as C-suite overhaul continues
30.03.Lilly presses for UK deal that would see higher drug prices in exchange for resumed investments: FT
30.03.United plots Tyvaso FDA filing after ph. 3 win elicits talk of 'new IPF standard' and blockbuster sales
30.03.BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters
30.03.Idorsia eyes pediatric insomnia use with midstage trial win for sleep med Quviviq
30.03.Takeda begins US layoffs as part of massive $1.3B restructuring
30.03.Samsung Biologics union gathers votes to strike as tension over wage, governance mounts